- This topic has 1 voice and 0 replies.
Viewing 0 reply threads
-
Posts
-
-
Antidote Technologies, a digital health company, and phaware global association, an organization advocating for pulmonary hypertension (PH) awareness, will join forces to create a new recruitment system for pharmaceutical companies and contract research organizations (CROs) to enroll patients with chronic lung diseases in their clinical trials.
The partnership will bring together phaware’s proven patient engagement model and Antidote’s expertise on recruitment for clinical trials, to improve the recruitment efficiency of patients with PH and related diseases. Click here to read more about this story.
What are your thoughts on this news?
-
Viewing 0 reply threads
- You must be logged in to reply to this topic.
